TITLE

Treatment of Severe Nausea/Vomiting-- An Evidence-Based Approach

AUTHOR(S)
Souney, Paul F.; Johnson, David
PUB. DATE
August 2000
SOURCE
American Journal of Gastroenterology;Aug2000, Vol. 95 Issue 8, p2121
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The American Society of Health-System Pharmacists (ASHP) has published therapeutic guidelines on a select group of disease states. The ASHP Therapeutic Guidelines for the pharmacological management of nausea and vomiting (NAV) were developed following a rigorous and formal examination of available medical literature. Using such an evidence-based medicine approach is important for the development of comprehensive scientifically based guidelines. The ASHP Therapeutic Guidelines for the pharmacological management of NAV were prepared by the University of Kentucky Drug Information Center working in conjunction with ASHP appointed clinical specialists represented by physicians, pharmacists, and nurses. The purpose of the paper is to assist health care professionals in managing NAV in both adult and pediatric patients undergoing chemotherapy, radiation therapy, or surgery. The guidelines are applicable to both an inpatient and outpatient setting. The authors cite the three primary reasons for guideline development as: 1) NAV occur frequently; 2) there is a lack of consistency in selection of therapeutic agents in clinical practice; and 3) NAV are preventable. The paper is divided into several sections. The first topics addressed are related to chemotherapy-induced NAV and include assessment of NAV and the physiology of chemotherapy-induced NAV (with subcategories of acute vs delayed NAV, breakthrough NAV, and anticipatory NAV). The drug review section for chemotherapy-induced NAV begins with factors to consider in the selection of and agent of chemotherapy-induced NAV, prevention of NAV, efficacy and selection of 5-HT3 receptor antagonists (alone or in combination with other agents), a special pediatric section, and pharamacoeconomic issues. Also included is a section on the treatment and prevention of breakthrough chemotherapy-induced NAV. The topics of radiation therapy-induced NAV and post-operative NAV are organized in a similar fashion starting with a review of physiology and continuing with factors to consider in the selection of agents and prevention and treatment. The following is a brief review of the three main topics covered in this article. Evaluation of each individual criterion is beyond the scope of this column.
ACCESSION #
17652333

 

Related Articles

  • Cyclic Vomiting Syndrome in Adults: Clinical Features and Response to Tricyclic Antidepressants. Prakash, Chandra; Clouse, Ray E. // American Journal of Gastroenterology;Oct1999, Vol. 94 Issue 10, p2855 

    OBJECTIVE: Cyclic vomiting syndrome (CVS) has been described infrequently in adults, and treatment in both children and adults remains unsatisfactory. We report clinical features of a group of adults with CVS and anecdotal outcome from open-label treatment with tricyclic antidepressants....

  • Antiemetic Therapy in Patients Receiving Cancer Chemotherapy. Marek, Cassandra // Oncology Nursing Forum;Mar/Apr2003, Vol. 30 Issue 2, p259 

    Presents a study which examined the available antiemetic medications and discussed their uses in the treatment of chemotherapy-induced nausea and vomiting. Mechanisms behind nausea and vomiting; Emetogenic potential of chemotherapy agents; Details on antiemetic agents.

  • Is Ondansetron More Effective Than Granisetron for Chemotherapy-Induced Nausea and Vomiting? A Review of Comparative Trials. Vrabel, Mark // Clinical Journal of Oncology Nursing;Dec2007, Vol. 11 Issue 6, p809 

    Nausea and vomiting are two of the most distressing side effects of chemotherapy. Guidelines recommend the use of 5-HT3 receptor antagonists as a pharmacologic intervention for acute and delayed nausea and vomiting for moderately and highly emetogenic chemotherapy. Although newer antiemetics and...

  • Nausea and Vomiting.  // American Family Physician;3/1/2004, Vol. 69 Issue 5, p1176 

    Offers information on nausea and vomiting. Causes of nausea and vomiting; Ways to manage nausea and vomiting; Signs that indicate nausea and vomiting as an underlying factor for a chronic condition.

  • Investigating Chemotherapy-Induced Nausea and Vomiting. Plaxe, Steven C. // Clinical Ovarian Cancer;Jun2008, Vol. 1 Issue 1, p66 

    In this article, the author discusses the study conducted by Timmins and colleagues on the efficacy of an antiemetic regimen in preventing chemotherapy-induced nausea and vomiting. He notes that despite the advancement in chemotherapy, gastrointestinal effects of chemotherapy remained as...

  • Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Eisenchlas, Jorge H; Garrigue, Nicolös; Junin, Marta; De Palliative, Gustavo Simone G // Palliative Medicine;Jan2005, Vol. 19 Issue 1, p71 

    Seventy patients with advanced cancer and refractory emesis were treated with subcutaneous boluses of levomepromazine (median daily dose: 6.25 mg; range: 3.12–25) in an open-label prospective study. Treatment was associated with a decrease in nausea from a median of 8/10 at baseline (IQR...

  • The cost of chemotherapy-induced nausea and vomiting in Italy. Enzo Ballatori; Fausto Roila; Benedetta Ruggeri; Stella Porrozzi; Mauro Iannopollo; Giancarla Soru; Giorgio Cruciani; Bruno Daniele; Maria Locatelli; James Pellissier; Robert Deuson // Supportive Care in Cancer;Jan2007, Vol. 15 Issue 1, p31 

    Abstract Goals of work?? The aim of this paper is to analyze the costs of chemotherapy-induced nausea and vomiting (CINV) in Italy. Materials and methods?? In this prospective observational study at seven public oncology centers, incidence and intensity of CINV daily for 8?days after...

  • Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. Münstedt, K; Müller, H; Blauth-Eckmeyer, E; Stenger, K; Zygmunt, M; Vahrson, H // British Journal of Cancer;2/1/99, Vol. 79 Issue 3/4, p637 

    Dexamethasone (20 mg) or its equivalent in combination with 5-HT[SUB3] antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is...

  • Placental transfer of ondansetron during early human pregnancy. Siu, Shing-Shun N.; Chan, Matthew T. V.; Lau, Tze-Kin // Clinical Pharmacokinetics;2006, Vol. 45 Issue 4, p419 

    Background and Objective: Nausea and vomiting are common conditions that occur during early pregnancy and can be disabling. Ondansetron had been used in pregnant women when treatment with conventional antiemetics has failed; however, the safety and tolerability of this relatively...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics